**Supplement materials**

**Supplemental Table 1. Demographic characteristics of patients with COVID-19 infected pneumonia**

|  |  |
| --- | --- |
| Study cohort (n=33) | No. (%) of patients |
| Age (Year, Median (range)) | 47 (2-84) |
| ≥ 60 years | 4 (12.1) |
| < 60 years | 29 (87.9) |
| Sex |  |
| Men | 17 (51.5) |
| Women | 16 (48.5) |
| Comorbid illness |  |
| Hypertension | 8 (24.2) |
| Diabetes | 3 (9.1) |
| Coronary arteriosclerosis | 2 (6.1) |
| Chronic liver diseases | 1 (3.0) |
| Common symptoms |  |
| Fever | 19 (57.6) |
| Cough | 17 (51.5) |
| Expectoration | 4 (12.1) |
| Fatigue | 3 (9.1) |
| Diarrhea | 3 (9.1) |
| Symptoms category |  |
| Respiratory symptoms only | 24 (72.7) |
| Respiratory and Gastrointestinal symptoms | 2 (6.1) |
| Gastrointestinal symptoms only | 1 (3.0) |
| Asymptomatic | 6 (18.2) |
| Radiographic findings |  |
| Bilateral infiltrate | 27 (81.8) |
| Unilateral infiltrate | 6 (18.2) |
| Duration before viral RNA undetectable  (Days, Median (IQR)) |  |
| Throat swab | 18.5 (13.25-22) |
| Sputum | 22 (18.5-27.5) |
| Stool | 17 (11.5-32) |
| Duration of symptoms before admission  (Days, Median (Range, IQR)) | 3 (0.5-15, 1.5-7) |
| Hospitalization (Days, Median (Range, IQR)) | 22 (16-30, 18-24) |
| Follow-up time (Days, Median (Range, IQR)) | 30 (12-38, 25-33.5) |

**Supplemental Table 2. Laboratory features of SARS-CoV-2 pneumonia at hospital admission and at the first return visit**

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameters** | **At admission** | **At the first return visit** | ***P* value** |
| **White blood cell (Mean (SD), ×109/L)** | 6.46 (5.68) | 5.7 (1.4) | 0.506 |
| **Normal (n, %)** | 24 (72.7%) | 25 (96.2%) |  |
| **Abnormal (n, %)** | 9 (27.3%) | 1 (3.8%) |  |
| **Neutrophil count (Mean (SD), ×109/L)** | 3.51 (1.85) | 3.3 (1.1) | 0.686 |
| **Normal (n, %)** | 29 (87.9%) | 25 (96.2%) |  |
| **Abnormal (n, %)** | 4 (12.1%) | 1 (3.8%) |  |
| **Lymphocyte count (Mean (SD), ×109/L)** | 1.57 (0.67) | 1.8 (0.5) | 0.210 |
| **Normal (n, %)** | 28 (84.8%) | 24 (92.3%) |  |
| **Abnormal (n, %)** | 5 (15.2%) | 2 (7.7%) |  |
| **Platelet count (Mean (SD), ×109/L)** | 204.8 (55.1) | 248.0 (54.3) | 0.001 |
| **Normal (n, %)** | 32 (97.0%) | 24 (92.3%) |  |
| **Abnormal (n, %)** | 1 (3.0%) | 2 (7.7%) |  |
| **C-reactive protein (Mean (SD), mg/L)** | 20.0 (25.7) | 1.8 (2.9) | 0.000 |
| **Normal (n, %)** | 18 (54.5%) | 25 (96.2%) |  |
| **Abnormal (n, %)** | 15 (45.5%) | 1 (3.8%) |  |
| **Creatine kinase (Mean (SD), U/L)** | 85.7 (53.7) | 61.7 (26.6) | 0.034 |
| **Normal (n, %)** | 31 (93.9%) | 26 (100%) |  |
| **Abnormal (n, %)** | 2 (6.1%) | 0 (0%) |  |
| **Lactate dehydrogenase (Mean (SD), U/L)** | 203.8 (61.1) | 171.2 (30.0) | 0.012 |
| **Normal (n, %)** | 23 (69.7%) | 25 (96.2%) |  |
| **Abnormal (n, %)** | 10 (30.3%) | 1 (3.8%) |  |
| **Blood urea nitrogen (Mean (SD),mmol/L)** | 3.8 (1.6) | 4.4 (1.3) | 0.411 |
| **Normal (n, %)** | 24 (72.7%) | 23 (88.5%) |  |
| **Abnormal (n, %)** | 9 (27.3%) | 3 (11.5%) |  |
| **Blood creatinine (Mean (SD), μmol/L)** | 84.8 (63.3) | 65.9 (20.2) | 0.341 |
| **Normal (n, %)** | 25 (75.8%) | 23 (88.5%) |  |
| **Abnormal (n, %)** | 8 (24.2%) | 3 (11.5%) |  |

**Supplement table 3. Comparison of viral RNA and antibodies between SARS-CoV-2 RNA short--persistence and long-persistence groups.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Short-persistence**  **(n=17)** | **Long-persistence**  **(n=16)** | ***P* value** |
| **Initial viral loads (Ct value, Median (IQR) )** | 28.1 (24.3-32.8) | 31.4 (27.7-30.0) | 0.364 |
| **Duration before viral RNA undetectable (Days, Median (IQR))** |  |  |  |
| **Throat swab** | 21 (15.5-22) | 18 (9-24) | 0.650 |
| **Stool** | 16 (9-28) | 18.5 (12.5-33.5) | 0.261 |
| **Duration of symptoms before admission (Days, Median (IQR))** | 2 (1-7) | 5 (2-10) | 0.048 |
| **Seroconversion time (Days, Median (IQR))** |  |  |  |
| **Anti-S IgM** | 10 (8-16) | 11 (7-15.5) | 0.532 |
| **Anti-RBD IgM** | 14 (8.5-24) | 14 (9-22) | 0.821 |
| **Anti-N IgM** | 10 (8.5-15.5) | 11 (6-14) | 0.524 |
| **Anti-S IgG** | 10 (7.5-14) | 12 (6-17) | 0.657 |
| **Anti-RBD IgG** | 12.5 (9.25-17.75) | 14 (8-17) | 0.914 |
| **Anti-N IgG** | 10 (7.25-12.25) | 9 (6-14) | 0.806 |
| **Antibody level (AU/ml, Median (IQR))** |  |  |  |
| **Anti-S IgM** | 1.99 (1.33-4.79) | 1.81 (1.69-2.09) | 0.128 |
| **Anti-RBD IgM** | 3.08 (1.50-5.37) | 1.5 (1.25-1.71) | 0.019 |
| **Anti-N IgM** | 2.02 (1.57-2.98) | 2.29 (1.30-3.34) | 0.363 |
| **Anti-S IgG** | 11.92 (4.19-17.68) | 9.17 (4.14-21.36) | 0.759 |
| **Anti-RBD IgG** | 7.75 (1.88-17.64) | 2.1 (1.32-6.53) | 0.152 |
| **Anti-N IgG** | 11.28 (2.91-20.44) | 7.24 (3.92-17.76) | 0.605 |
| **Antibody peak time (Days, Median (IQR))** |  |  |  |
| **Anti-S IgM** | 24 (11-33.5) | 21 (16.5-25.5) | 0.918 |
| **Anti-RBD IgM** | 28 (15.25-36.25) | 25 (17.5-39) | 0.813 |
| **Anti-N IgM** | 17 (9.25-28.25) | 11 (7.5-19) | 0.458 |
| **Anti-S IgG** | 29 (20-35.5) | 37 (20-40) | 0.580 |
| **Anti-RBD IgG** | 29.5 (19-35) | 32 (22-39) | 0.266 |
| **Anti-N IgG** | 28 (15.75-32) | 26 (17-39) | 0.509 |
| **Peak level (AU/ml, Median (IQR))** |  |  |  |
| **Anti-S IgM** | 6.39 (1.71-11.11) | 2.1 (1.75-2.79) | 0.019 |
| **Anti-RBD IgM** | 5.56 (2.06-25.07) | 1.78 (1.35-2.59) | 0.037 |
| **Anti-N IgM** | 2.37 (1.94-3.03) | 2.96 (1.47-4.46) | 0.337 |
| **Anti-S IgG** | 26.28 (7.53-67.76) | 22.28 (15.12-41.4) | 0.493 |
| **Anti-RBD IgG** | 20.7 (7.08-43.49) | 19.28 (9.74-29.6) | 0.503 |
| **Anti-N IgG** | 29.68 (14.04-47.56) | 31.36 (13.08-42.56) | 0.682 |